Enhanced Activity against Multi-drug Resistant Bacteria through Coapplication of an Analogue of Tachyplesin I and an Inhibitor of the QseC/B Signaling Pathway.

JOURNAL OF MEDICINAL CHEMISTRY(2020)

引用 21|浏览29
暂无评分
摘要
Tachyplesin I (TPI) is a cationic beta-hairpin antimicrobial peptide with broad-spectrum, potent antimicrobial activity. In this study, the all D-amino acid analogue of TPI (TPAD) was synthesized, and its structure and activity were determined. TPAD has comparable antibacterial activity to TPI on 14 bacterial strains, including four drug-resistant bacteria. Importantly, TPAD has significantly improved stability against enzymatic degradation and decreased hemolytic activity compared to TPI, indicating that it has better therapeutic potential. The induction of bacterial resistance using low concentrations of TPAD resulted in the activation of the QseC/B two-component system. Deletion of this system resulted in at least five-fold improvement of TPAD activity, and the combined use of TPAD with LED209, a QseC/B inhibitor, significantly enhanced the bactericidal effect against three classes of multidrug-resistant bacteria.
更多
查看译文
关键词
inhibitor,bacteria,tachyplesin,multidrug-resistant
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要